AbbVie Seeks Strict Interchangeability Standards For Biosimilars

Interchangeability must be demonstrated for every indication on reference product's label even if biosimilar is not approved for all the same uses, AbbVie says in citizen petition filed three weeks after Amgen submitted a 351(k) application referencing Humira.